The Pharma Data

OCTOBER 28, 2020

We appreciate the confidence of the MHLW in Moderna and mRNA-1273, which we hope will help address the pandemic, especially given the encouraging data we have recently published together with the NIH related to the clinical trial in the elderly and older adult population,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “We

Vaccination 40

Vaccination Vaccine Manufacturing Clinical Trials 40

The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations. www.sec.gov. www.sec.gov.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

OCTOBER 25, 2020

mRNA-1273 is currently being studied in a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at the 100 µg dose level in the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Development 52

The Pharma Data

DECEMBER 8, 2020

Recently released interim Phase 1 further indicates that 90 days following the second vaccination, trial participants retained high levels of neutralizing antibodies, suggesting that mRNA-1273 can generate durable neutralizing antibodies across all age groups including in older and elderly adults. Department of Health and Human Services.

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40

The Pharma Data

NOVEMBER 16, 2020

I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, and the staff at our clinical trial sites who have been on the front lines of the fight against the virus. The trial will continue to accrue additional data relevant to safety and efficacy even after an EUA is submitted. ages 18 and older.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 19, 2020

The Moderna COVID-19 Vaccine (previously referred to as mRNA-1273) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center. About the Moderna COVID-19 Vaccine.

Vaccination 52

Vaccination Vaccine Licensing Licensing 52

The Pharma Data

JANUARY 24, 2021

Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio. “We Molnupiravir is currently being evaluated in Phase 2/3 clinical trials in both the hospital and out-patient settings.

Development 52

Development Vaccination Vaccine Production 52

The Pharma Data

NOVEMBER 16, 2020

mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center. Food and Drug Administration (FDA) to submit data from its ongoing stability testing for approval. About mRNA-1273.

Vaccination 52

Vaccination Vaccine Containment Pharmacy 52

The Pharma Data

DECEMBER 2, 2020

Hemophilia is a genetic hematological rare disease that results in a deficiency of a protein that is required for normal blood clotting—clotting factor VIII in hemophilia A and clotting factor IX in hemophilia B. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. About the BASIS study. About Hemophilia.

Containment 52

Containment Development Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 21, 2020

Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, by visiting EDGAR on the SEC website at www.sec.gov or from: J.P. 6132, or by e-mail at syndicate@svbleerink.com or Barclays Capital Inc.,

Gene Therapy 40

Gene Therapy Immune Response Sales Gene 40

Pfizer

JANUARY 27, 2023

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Marketing 75

Marketing Production Drugs Licensing 75

The Pharma Data

OCTOBER 19, 2020

The V114 Phase 3 clinical development program is comprised of 16 trials investigating the safety, tolerability and immunogenicity of V114 in a variety of populations who are at increased risk for pneumococcal disease, including healthy older adults and children, as well as people who are immunocompromised or have certain chronic medical conditions.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

The Pharma Data

JANUARY 6, 2021

The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. Source link.

Vaccination 52

Vaccination Vaccine Development Marketing 52

The Pharma Data

JULY 8, 2021

Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Genetics 52

Genetics Biobanking Protein Containment 52

Pfizer

OCTOBER 19, 2022

Today’s recommendation is based on data from a Phase 2/3 randomized, controlled trial that included 4,526 children aged 6 months to less than 5 years. Today’s recommendation is based on data from a Phase 2/3 randomized, controlled trial that included 4,526 children aged 6 months to less than 5 years. 2 was the predominant variant.

Vaccination 40

Vaccination Vaccine Clinical Trials Clinical Trials 40

The Pharma Data

JANUARY 15, 2021

1] Darzalex Faspro® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to the deterioration of vital organs, most notably the heart, kidneys and liver.[2],[3] [1] DARZALEX FASPRO® Prescribing Information.

FDA Approval 52

FDA Approval Production Research Doctors 52

Pfizer

SEPTEMBER 28, 2022

This study is consistent with regulatory guidance and follows the design of the previous Phase 1/2/3 trial to evaluate further options for protection in this age group. . Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus .

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

The Pharma Data

FEBRUARY 8, 2021

6] ERLEADA ® is being studied in five Phase 3 registrational clinical trials. 2% over placebo) from the randomized placebo-controlled clinical trials (TITAN and SPARTAN) were fatigue, arthralgia, rash, decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhea and fracture. All rights reserved.

HR 52

HR Hormones Development Production 52

Pfizer

SEPTEMBER 16, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . COMIRNATY® (COVID-19 Vaccine, mRNA) INDICATION. Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Marketing 75

Marketing Vaccination Vaccine Clinical Trials 75

The Pharma Data

DECEMBER 17, 2020

Copies of the final prospectus may be obtained, when available, on the SEC’s website, www.sec.gov , or by contacting Aegis Capital Corp., GP2 is a 9 amino acid transmembrane peptide of the HER2/ neu protein. The public offering equates to 660,000 shares of the Company’s common stock at a price of $40.00

Clinical Trials 52

Clinical Trials Clinical Trials Containment Trials 52

Pfizer

DECEMBER 13, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Drugs 110

Drugs Licensing Licensing Production 110

Pfizer

DECEMBER 20, 2022

Results from these analyses are consistent with previously disclosed efficacy and safety data for the trials. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide.

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

JUNE 18, 2021

PREVNAR 20 includes capsular polysaccharide conjugates for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) already included in Prevnar 13 ® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM 197 Protein]). Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Atlanta, GA.

Vaccination 52

Vaccination Vaccine FDA Approval Containment 52

Pfizer

NOVEMBER 23, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

The Pharma Data

FEBRUARY 8, 2021

Patients in the trial received either a combination of ERLEADA ® and ZYTIGA ® plus prednisone (combination arm) or placebo and ZYTIGA ® plus prednisone (control arm). [i] v] ERLEADA ® is being studied in five Phase 3 clinical trials. For more information about ERLEADA ® , visit www.ERLEADA.com. *© All rights reserved.

HR 52

HR In-Vitro Development Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. A Phase 3 trial is ongoing. Protease Inhibitor Program. Rare Disease.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

Pfizer

OCTOBER 20, 2022

PREVNAR 20® is Pfizer’s next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) already included in Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).

Vaccination 40

Vaccination Vaccine Containment Immune Response 40

The Pharma Data

JANUARY 12, 2021

as the Moderna COVID-19 Vaccine) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center. The COVID-19 Vaccine Moderna (referred to in the U.S.

Vaccination 52

Vaccination Vaccine Manufacturing Containment 52

The Pharma Data

JANUARY 6, 2021

as the Moderna COVID-19 Vaccine) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center. The COVID-19 Vaccine Moderna (referred to in the U.S.

Vaccination 52

Vaccination Vaccine Medicine Containment 52

The Pharma Data

NOVEMBER 30, 2020

I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, as well as the staff at clinical trial sites who have been on the front lines of the fight against the virus. The trial will continue to accrue additional data relevant to safety and efficacy even after an EUA is submitted.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

Pfizer

NOVEMBER 2, 2022

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the advancement of an mRNA-based combination vaccine candidate for influenza and COVID-19 to a Phase 1 trial with the aim to address two severe respiratory diseases with one vaccine. Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) INDICATION.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Pfizer

DECEMBER 8, 2022

Pfizer and BioNTech previously announced the start of a Phase 1 trial to examine the safety, tolerability, and immunogenicity of their combined influenza and COVID-19 candidate vaccine among healthy adults. . SARS-CoV-2 led to a global pandemic with more than 6.5 million deaths ii and a high socio-economic burden worldwide. INDICATION.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

The Pharma Data

JANUARY 4, 2021

The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center. About the Moderna COVID-19 Vaccine.

Vaccination 52

Vaccination Vaccine Medicine Containment 52

The Pharma Data

MAY 13, 2021

To date, more than 225,000 individuals participating in clinical trials and vaccination initiatives have received at least the first dose of the Johnson & Johnson Ebola vaccine regimen, including 180,000 who have been fully vaccinated. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52